← Back to headlines
Moderna Reaffirms 2026 Revenue Growth Target, Lowers Cash Cost Guidance
Moderna has reiterated its target of up to 10% revenue growth for 2026 while simultaneously lowering its cash cost guidance to approximately $4 billion. The company also expects 55% of its second-half revenue in Q3, despite a norovirus trial missing an early metric.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
